{
    "nctId": "NCT04434404",
    "briefTitle": "Evaluation of the Cardioprotective Effect of L-carnitine and Silymarin in Patients Receiving Anthracycline Chemotherapy",
    "officialTitle": "Cardioprotection of Silymarin for Patients Received Anthracycline Chemotherapy",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 83,
    "primaryOutcomeMeasure": "The use of l-carnitine may be of use in extending the continuous use of anthracycline-containing chemotherapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* cancer patients receiving anthracycline chemotherapy in their protocol alone (without any cardioprotective agent),\n* aged 20-60 and\n* female patients were included.\n\nExclusion Criteria:\n\n* patients with a history of heart failure, arrhythmia, history of cardiac catheterizations or, history of angina, uncontrolled hypertension and uncontrolled diabetes,\n* patients with impaired liver function tests,\n* previous anthracycline-containing regimens and any cardiotoxic chemotherapy regimens,\n* previous history of chest wall irradiation.\n* Brain metastasis,\n* pregnant patients and\n* patients who refused informed consent,",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT"
}